MDK74978 | CAS#778274-97-8 | Multi-kinase inhibitor

MedKoo Cat#: 558268 | Name: MDK74978

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MDK74978, also known as Multi-kinase inhibitor I, is a Multi-kinase inhibitor. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

Chemical Structure

MDK74978

CAS#778274-97-8

Theoretical Analysis

MedKoo Cat#: 558268

Name: MDK74978

CAS#: 778274-97-8

Chemical Formula: C20H17F3N4O3

Exact Mass: 418.1253

Molecular Weight: 418.38

Elemental Analysis: C, 57.42; H, 4.10; F, 13.62; N, 13.39; O, 11.47

Price and Availability

Size	Price	Availability
250mg	USD 1,650.00	2 Weeks
500mg	USD 2,950.00	2 Weeks
1g	USD 3,650.00	2 Weeks
2g	USD 5,850.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

MDK74978; MDK-74978; MDK 74978. Multi-kinase inhibitor I

IUPAC/Chemical Name

N-(2-Hydroxyethyl)-4-[6-[4-(trifluoromethoxy)anilino]pyrimidin-4-yl]benzamide

InChi Key

DEGDCVFNFAOIPU-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H17F3N4O3/c21-20(22,23)30-16-7-5-15(6-8-16)27-18-11-17(25-12-26-18)13-1-3-14(4-2-13)19(29)24-9-10-28/h1-8,11-12,28H,9-10H2,(H,24,29)(H,25,26,27)

SMILES Code

O=C(NCCO)C1=CC=C(C2=NC=NC(NC3=CC=C(OC(F)(F)F)C=C3)=C2)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 418.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Chang Hsu Y, Selvaraj Coumar M, Wang WC, Shiao HY, Ke YY, Lin WH, Kuo CC, Chang CW, Kuo FM, Chen PY, Wang SY, Li AS, Chen CH, Kuo PC, Chen CP, Wu MH, Huang CL, Yen KJ, Chang YI, Hsu JT, Chen CT, Yeh TK, Song JS, Shih C, Hsieh HP. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. Oncotarget. 2016 Nov 15. doi: 10.18632/oncotarget.13369. [Epub ahead of print] PubMed PMID: 27863392. 2: García-Vilas JA, Pino-Ángeles A, Martínez-Poveda B, Quesada AR, Medina MÁ. The noni anthraquinone damnacanthal is a multi-kinase inhibitor with potent anti-angiogenic effects. Cancer Lett. 2017 Jan 28;385:1-11. doi: 10.1016/j.canlet.2016.10.037. PubMed PMID: 27816491. 3: Li Y, Tang K, Zhang L, Li C, Niu F, Zhou W, Yang H, Feng Z, Chen X. The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth. Cancer Lett. 2015 Jan 28;356(2 Pt B):392-403. doi: 10.1016/j.canlet.2014.09.040. PubMed PMID: 25301453. 4: Li JP, Huang ZJ, Lu XS, Zhou YC, Shao Y, He XP, Chen SR, Wang DD, Qin LS, Sun WH. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells. Oncotarget. 2016 Oct 21. doi: 10.18632/oncotarget.12802. [Epub ahead of print] PubMed PMID: 27780925. 5: Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Ray-Coquard I, Meeus P, Fayette J, Flechon A, Le Cesne A, Penel N, Tredan O, Blay JY. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. Oncotarget. 2015 Sep 22;6(28):26388-99. doi: 10.18632/oncotarget.4557. PubMed PMID: 26317543; PubMed Central PMCID: PMC4694909. 6: Roboz GJ, Khoury HJ, Jabbour E, Session W, Ritchie EK, Miao H, Faderl S, Zheng W, Feldman EJ, Arellano M, Morrison JG, Ravandi F. Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leuk Lymphoma. 2015 Feb;56(2):395-400. doi: 10.3109/10428194.2014.918970. PubMed PMID: 24794806. 7: Cuenca-López MD, Serrano-Heras G, Montero JC, Corrales-Sánchez V, Gomez-Juarez M, Gascón-Escribano MJ, Morales JC, Voisin V, Núñez LE, Morís F, Bader GD, Pandiella A, Ocaña A. Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer. Oncotarget. 2015 Sep 29;6(29):27923-37. doi: 10.18632/oncotarget.4736. PubMed PMID: 26314846; PubMed Central PMCID: PMC4695035. 8: Hotta K, Ueyama J, Tatsumi Y, Tsukiyama I, Sugiura Y, Saito H, Matsuura K, Hasegawa T. Lack of Contribution of Multidrug Resistance-associated Protein and Organic Anion-transporting Polypeptide to Pharmacokinetics of Regorafenib, a Novel Multi-Kinase Inhibitor, in Rats. Anticancer Res. 2015 Sep;35(9):4681-9. PubMed PMID: 26254357. 9: Cicenas J, Cicenas E. Multi-kinase inhibitors, AURKs and cancer. Med Oncol. 2016 May;33(5):43. doi: 10.1007/s12032-016-0758-4. Review. PubMed PMID: 27038473. 10: Martinez-Gil L, Alamares-Sapuay JG, Ramana Reddy MV, Goff PH, Premkumar Reddy E, Palese P. A small molecule multi-kinase inhibitor reduces influenza A virus replication by restricting viral RNA synthesis. Antiviral Res. 2013 Oct;100(1):29-37. doi: 10.1016/j.antiviral.2013.07.010. PubMed PMID: 23891991. 11: Colzani M, Noberini R, Romanenghi M, Colella G, Pasi M, Fancelli D, Varasi M, Minucci S, Bonaldi T. Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810. Mol Cell Proteomics. 2014 Jun;13(6):1495-509. doi: 10.1074/mcp.M113.034173. PubMed PMID: 24696502; PubMed Central PMCID: PMC4047469. 12: Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K, Tamura T. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. BMC Cancer. 2014 Jul 21;14:530. doi: 10.1186/1471-2407-14-530. PubMed PMID: 25047123; PubMed Central PMCID: PMC4223557. 13: Pallis M, Abdul-Aziz A, Burrows F, Seedhouse C, Grundy M, Russell N. The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells. Br J Haematol. 2012 Oct;159(2):191-203. doi: 10.1111/bjh.12018. PubMed PMID: 22934750. 14: Kuo WL, Liu J, Mauceri H, Vokes EE, Weichselbaum R, Rosner MR, Cohen EE. Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther. 2010 Oct;9(10):2814-24. doi: 10.1158/1535-7163.MCT-10-0352. PubMed PMID: 20876745; PubMed Central PMCID: PMC2953602. 15: Kataoka Y, Mukohara T, Tomioka H, Funakoshi Y, Kiyota N, Fujiwara Y, Yashiro M, Hirakawa K, Hirai M, Minami H. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks. Invest New Drugs. 2012 Aug;30(4):1352-60. doi: 10.1007/s10637-011-9699-0. PubMed PMID: 21655918. 16: Gahr S, Wissniowski T, Zopf S, Strobel D, Pustowka A, Ocker M. Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. J Cancer. 2012;3:158-65. doi: 10.7150/jca.4211. PubMed PMID: 22514558; PubMed Central PMCID: PMC3328781. 17: Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S, Keer H, Miles D, Müller T, Lorusso P. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs. 2013 Jun;31(3):742-50. doi: 10.1007/s10637-012-9881-z. Erratum in: Invest New Drugs. 2015 Dec;33(6):1292. PubMed PMID: 23054208. 18: Albanese C, Alzani R, Amboldi N, Degrassi A, Festuccia C, Fiorentini F, Gravina G, Mercurio C, Pastori W, Brasca M, Pesenti E, Galvani A, Ciomei M. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier. Br J Pharmacol. 2013 May;169(1):156-66. doi: 10.1111/bph.12112. PubMed PMID: 23347136; PubMed Central PMCID: PMC3632246. 19: Hasinoff BB, Wu X, Nitiss JL, Kanagasabai R, Yalowich JC. The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II. Biochem Pharmacol. 2012 Dec 15;84(12):1617-26. doi: 10.1016/j.bcp.2012.09.023. PubMed PMID: 23041231; PubMed Central PMCID: PMC3501595. 20: Buchanan CM, Shih JH, Astin JW, Rewcastle GW, Flanagan JU, Crosier PS, Shepherd PR. DMXAA (Vadimezan, ASA404) is a multi-kinase inhibitor targeting VEGFR2 in particular. Clin Sci (Lond). 2012 May 1;122(10):449-57. doi: 10.1042/CS20110412. PubMed PMID: 22142330.